Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Renal Cell Carcinoma – Current Treatment – Current Treatment: Physician Insights – Renal Cell Carcinoma (US)
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…
Heart Failure | Reduced Ejection Fraction | Treatment Algorithms: Claims Data Analysis | US | 2023
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers…
Heart Failure | Preserved Ejection Fraction | Treatment Algorithms: Claims Data Analysis | US | 2023
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved…
Coronavirus COVID-19 – Special Topics – Special Topics: COVID-19 Treatment and Management (G7 )
The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral…
Ovarian Cancer – Unmet Need – Unmet Need – Advanced Platinum-Sensitive Ovarian Cancer (US/EU)
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s…
Growth Hormone Deficiency – Executive Insights – Growth hormone deficiency: Executive Insights (US)
Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often…
Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)
The approvals of anti-PD-1/PD-L1 therapies—Keytruda (Merck & Co.), Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA)—and antibody-drug conjugates—Padcev (Seagen / Astellas) and…
Multiple Sclerosis – Unmet Need – Unmet Need – Primary-Progressive Multiple Sclerosis (US/EU)
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
